|
Name |
(8R,9R,10S,13S,14R,17S)-17-[(E,2S,5R)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
|
| Molecular Formula | C29H46O | |
| IUPAC Name* |
(8R,9R,10S,13S,14R,17S)-17-[(E,2S,5R)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
|
|
| SMILES |
CC[C@@H](/C=C/[C@H](C)[C@@H]1CC[C@H]2[C@]1(CC[C@@H]3[C@@H]2CCC4=CC(=O)CC[C@@]34C)C)C(C)C
|
|
| InChI |
InChI=1S/C29H46O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-9,18-21,24-27H,7,10-17H2,1-6H3/b9-8+/t20-,21-,24+,25-,26+,27+,28+,29-/m0/s1
|
|
| InChIKey |
MKGZDUKUQPPHFM-HGIKXSOESA-N
|
|
| Synonyms |
Stigmasta-4,22-dien-3-one; 55722-32-2
|
|
| CAS | NA | |
| PubChem CID | 133612144 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 410.7 | ALogp: | 8.5 |
| HBD: | 0 | HBA: | 1 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 17.1 | Aromatic Rings: | 4 |
| Heavy Atoms: | 30 | QED Weighted: | 0.401 |
| Caco-2 Permeability: | -4.7 | MDCK Permeability: | 0.00002130 |
| Pgp-inhibitor: | 0.969 | Pgp-substrate: | 0.011 |
| Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.825 |
| 30% Bioavailability (F30%): | 0.963 |
| Blood-Brain-Barrier Penetration (BBB): | 0.025 | Plasma Protein Binding (PPB): | 88.71% |
| Volume Distribution (VD): | 1.214 | Fu: | 0.99% |
| CYP1A2-inhibitor: | 0.109 | CYP1A2-substrate: | 0.542 |
| CYP2C19-inhibitor: | 0.281 | CYP2C19-substrate: | 0.948 |
| CYP2C9-inhibitor: | 0.39 | CYP2C9-substrate: | 0.111 |
| CYP2D6-inhibitor: | 0.131 | CYP2D6-substrate: | 0.116 |
| CYP3A4-inhibitor: | 0.944 | CYP3A4-substrate: | 0.901 |
| Clearance (CL): | 6.913 | Half-life (T1/2): | 0.139 |
| hERG Blockers: | 0.635 | Human Hepatotoxicity (H-HT): | 0.332 |
| Drug-inuced Liver Injury (DILI): | 0.772 | AMES Toxicity: | 0.007 |
| Rat Oral Acute Toxicity: | 0.665 | Maximum Recommended Daily Dose: | 0.935 |
| Skin Sensitization: | 0.865 | Carcinogencity: | 0.174 |
| Eye Corrosion: | 0.216 | Eye Irritation: | 0.061 |
| Respiratory Toxicity: | 0.983 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001764 | ![]() |
0.729 | D06XMU | ![]() |
0.596 | ||
| ENC002882 | ![]() |
0.729 | D07BSQ | ![]() |
0.581 | ||
| ENC005239 | ![]() |
0.729 | D02CJX | ![]() |
0.534 | ||
| ENC001545 | ![]() |
0.694 | D0W5LS | ![]() |
0.528 | ||
| ENC001846 | ![]() |
0.657 | D0Z1XD | ![]() |
0.500 | ||
| ENC003369 | ![]() |
0.657 | D0Y7LD | ![]() |
0.495 | ||
| ENC002290 | ![]() |
0.640 | D0G8BV | ![]() |
0.470 | ||
| ENC004758 | ![]() |
0.583 | D02AXG | ![]() |
0.463 | ||
| ENC001558 | ![]() |
0.583 | D08TEJ | ![]() |
0.442 | ||
| ENC002665 | ![]() |
0.552 | D00AEQ | ![]() |
0.432 | ||